AbbVie Inc. (NYSE: ABBV) is a global, research-driven biopharmaceutical company with leadership positions in immunology, oncology, neuroscience, aesthetics and eye care, built around products such as Skyrizi, Rinvoq and the Allergan-derived Botox and Juvederm franchises. This page brings together live AbbVie market data, charting, financials, technical indicators, company details, recent news and a clearly labelled Shariah-screening snapshot for research purposes. Market data and widgets below update dynamically; Shariah status should be treated as time-sensitive and independently verified.
Key Investor Considerations for AbbVie
Potential Strengths
- Skyrizi and Rinvoq have scaled into a combined immunology franchise that has more than offset Humira’s biosimilar-driven revenue decline
- Diversified therapeutic-area exposure across immunology, oncology, neuroscience, aesthetics and eye care
- Aesthetics franchise (Botox Cosmetic, Juvederm) provides a revenue stream with different demand drivers and patent dynamics than prescription pharmaceuticals
- Long history of annual dividend increases, including years as part of Abbott Laboratories prior to the 2013 spin-off, widely cited as Dividend King status
- Active pipeline replenishment through internal R&D and bolt-on acquisitions such as Cerevel Therapeutics, ImmunoGen and the announced Apogee Therapeutics transaction
- Established global commercial infrastructure spanning multiple specialty and primary-care markets
Material Risks
- Continued Humira revenue erosion from biosimilar competition in the U.S. and other markets
- Future loss-of-exclusivity risk facing other key products over time
- Elevated debt levels associated with large acquisitions, including Allergan, Cerevel, ImmunoGen and Apogee
- U.S. drug-pricing and regulatory reform, including Medicare price-negotiation exposure
- Clinical and regulatory failure risk inherent to early- and late-stage pipeline assets
- Intense competition from Johnson & Johnson, Pfizer, Novartis, Eli Lilly, Amgen and other large biopharmaceutical companies across immunology and oncology
Frequently Asked Questions
What does AbbVie Inc. do?
AbbVie is a global biopharmaceutical company that discovers, develops, manufactures and sells medicines and therapies across immunology, oncology, neuroscience, aesthetics and eye care, including products such as Skyrizi, Rinvoq, Humira, Botox Cosmetic and Botox Therapeutic.
On which exchange is AbbVie listed?
AbbVie Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol ABBV.
What are AbbVie’s main business segments?
AbbVie reports its operations as a single reportable segment per its most recent Form 10-K, while disclosing revenue across therapeutic areas including immunology, oncology, neuroscience, aesthetics, and eye care and other specialty products.
How is AbbVie managing Humira’s decline?
Since U.S. biosimilar competition began in 2023, Humira revenue has declined significantly. AbbVie has offset that decline primarily through growth in Skyrizi and Rinvoq, its next-generation immunology products, which together generate substantially more revenue than Humira did at its peak.
Does AbbVie pay a dividend?
Yes. AbbVie pays a quarterly dividend and has increased it annually for a multi-decade streak that, when its history as part of Abbott Laboratories is included, is widely cited as qualifying it for Dividend King status. Investors should verify the current streak length and payout through AbbVie’s investor relations page before relying on it.
Who are AbbVie’s main competitors?
AbbVie competes with large biopharmaceutical companies including Johnson & Johnson, Pfizer, Merck, Eli Lilly, Amgen, Novartis, Roche and Bristol Myers Squibb across its immunology, oncology and other therapeutic areas.
Is AbbVie stock currently Shariah compliant?
Zoya screens ABBV as Shariah-compliant under AAOIFI standards, last updated August 2026, citing interest income of roughly 0.43% of combined revenue for the fiscal year ended December 31, 2025. This page checked only Zoya as a screening source; investors should confirm current status through a named provider or qualified Shariah adviser before relying on it.
Conclusion
AbbVie has spent the years since its 2013 spin-off from Abbott Laboratories building a diversified biopharmaceutical business spanning immunology, oncology, neuroscience, aesthetics and eye care, most notably navigating Humira’s biosimilar-driven decline by scaling Skyrizi and Rinvoq into its primary immunology growth engines. The 2020 Allergan acquisition added a distinct aesthetics franchise in Botox Cosmetic and Juvederm, while more recent acquisitions such as Cerevel Therapeutics, ImmunoGen and the announced Apogee Therapeutics transaction reflect continued investment in replenishing the pipeline. That position is balanced against ongoing loss-of-exclusivity risk, elevated acquisition-related debt, U.S. drug-pricing and regulatory pressure, and competition from other large biopharmaceutical companies across immunology and oncology. The tools on this page — charts, financials, technical indicators and news — support ongoing research into AbbVie’s position, but they do not replace a review of AbbVie’s official filings or independent financial, legal, tax or Shariah advice.
